O-Trifluoromethyl-L-tyrosine
Need Assistance?
  • US & Canada:
    +
  • UK: +

O-Trifluoromethyl-L-tyrosine

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Category
Fluorinated amino acids
Catalog number
BAT-001665
CAS number
131123-44-9
Molecular Formula
C10H10F3NO3
Molecular Weight
249.19
IUPAC Name
(2S)-2-amino-3-[4-(trifluoromethoxy)phenyl]propanoic acid
Synonyms
H-Tyr(CF3)-OH; H-Phe(4-OCF3)-OH; (2S)-2-amino-3-[4-(trifluoromethoxy)phenyl]propanoic acid; 4-Trifluoromethoxy-L-phenylalanine
Purity
> 98 %
Density
1.401±0.06 g/cm3(Predicted)
Boiling Point
309.1±42.0 °C(Predicted)
Storage
Store at RT
InChI
InChI=1S/C10H10F3NO3/c11-10(12,13)17-7-3-1-6(2-4-7)5-8(14)9(15)16/h1-4,8H,5,14H2,(H,15,16)/t8-/m0/s1
InChI Key
YZXUCQCJZKJMIR-QMMMGPOBSA-N
Canonical SMILES
C1=CC(=CC=C1CC(C(=O)O)N)OC(F)(F)F
1. Influence of nitisinone and its metabolites on l-tyrosine metabolism in a model system
Joanna Płonka, Monika Babiuch, Hanna Barchanska Chemosphere. 2022 Jan;286(Pt 1):131592. doi: 10.1016/j.chemosphere.2021.131592. Epub 2021 Jul 19.
Nitisinone (NTBC) is currently used for the treatment of tyrosinemia type 1, a rare disease. It also exhibits potential in the treatment of other orphan diseases as well as nervous system disorders - this is however limited by its side effects. In all living organisms, NTBC inhibits 4-hydroxyphenylpyruvate dioxygenase activity, thereby affecting l-tyrosine (L-TYR) catabolism, which results in the therapeutic effect. The NTBC metabolites formed in patient's body is one of the causes of its side effects. The influence of NTBC and its metabolites; 2-amino-4-(trifluoromethyl)benzoic acid, 2-nitro-4-(trifluoromethyl)benzoic acid, and cyclohexane-1,3-dione on L-TYR catabolism was investigated in Raphanus sativus var. longipinnatus. Based on targeted LC-MS/MS analysis the concentration of NTBC and its metabolites in exposed plant tissues was determined. Based on non-targeted LC-MS/MS analysis the concentrations of products of L-TYR catabolism: levodopa, epinephrine, norepinephrine, normetanephrine, dopamine, tyramine and vitamins C, B5 and B6, additionally leucine and valine were identified as influenced by the NTBC or its metabolites. NTBC and its metabolites influenced L-TYR catabolism differently. Particularly significant changes were found in the content of epinephrine and normetanephrine: in the plant tissues exposed to NTBC, an increase in the content of these neurotransmitters was found (+42%), whereas in the plant treated with 2-amino-4-(trifluoromethyl)benzoic acid or 2-nitro-4-(trifluoromethyl)benzoic acid a decrease in concentration (-39% and 55%, respectively) was observed. Cyclohexane-1,3-dione does not influence epinephrine and normetanephrine concentration. The conclusions of this study provide a platform for expanded research on the causes of side effects of NTBC treatment.
2. Striatal-enriched Tyrosine Protein Phosphatase (STEP) in the Mechanisms of Depressive Disorders
Elizabeth Kulikova, Alexander Kulikov Curr Protein Pept Sci. 2017 Aug 30;18(11):1152-1162. doi: 10.2174/1389203718666170710121532.
Striatal-enriched tyrosine protein phosphatase (STEP) is expressed mainly in the brain. Its dysregulation is associated with Alzheimer's and Huntington's diseases, schizophrenia, fragile X syndrome, drug abuse and stroke/ischemia. However, an association between STEP and depressive disorders is still obscure. The review discusses the theoretical foundations and experimental facts concerning possible relationship between STEP dysregulation and depression risk. STEP dephosphorylates and inactivates several key neuronal signaling proteins such as extracellular signal-regulating kinase 1 and 2 (ERK1/2), stress activated protein kinases p38, the Src family tyrosine kinases Fyn, Pyk2, NMDA and AMPA glutamate receptors. The inactivation of these proteins decreases the expression of brain derived neurotrophic factor (BDNF) necessary for neurogenesis and neuronal survival. The deficit of BDNF results in progressive degeneration of neurons in the hippocampus and cortex and increases depression risk. At the same time, a STEP inhibitor, 8-(trifluoromethyl)-1,2,3,4,5-benzopentathiepin-6-amine hydrochloride (TC-2153), increases BDNF expression in the hippocampus and attenuated the depressivelike behavior in mice. Thus, STEP is involved in the mechanism of depressive disorders and it is a promising molecular target for atypical antidepressant drugs of new generation.
Online Inquiry
Verification code
Inquiry Basket